Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naive Patients With HER2-Positive Breast Cancer

NCT00712881 is registered in ClinicalTrials.gov with Cephalon, Inc. as lead sponsor.

NCT NCT00712881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00712881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naive Patients With HER2-Positive Breast Cancer
Lead sponsor
Cephalon, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 13, 2008
Completion date
September 17, 2015
Enrollment
126 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer